MiNK Therapeutics, Inc.
INKT- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001840229
No open-market purchases or sales by MiNK Therapeutics, Inc. insiders were filed in the last 90 days; 27 institutions reported holding it in 13F filings for Q2 2026, worth $2.39M in total; no superinvestor holds it.
13F holders, Q1 2022
Institutional positions in MiNK Therapeutics, Inc. as of Mar 31, 2022. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 25
- +4 vs. Q4 2021
- Shares held
- 782.8K
- −554.7K (−41.5%) vs. Q4 2021
- Total value
- $1.76M
- −$4.20M (−70.5%) vs. Q4 2021
- New holders
- 8
- 6 more added
- Sold out
- 4
- 8 more reduced
Compare with Q4 2021: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting INKT on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 27 | $2.39M |
| Q1 2026 | 23 | $1.34M |
| Q4 2025 | 25 | $1.71M |
| Q3 2025 | 18 | $1.28M |
| Q2 2025 | 19 | $460.8K |
| Q1 2025 | 17 | $544.2K |
| Q4 2024 | 23 | $564.9K |
| Q3 2024 | 26 | $632.3K |
| Q2 2024 | 31 | $847.8K |
| Q1 2024 | 34 | $848.1K |
| Q4 2023 | 36 | $1.05M |
| Q3 2023 | 36 | $800.0K |
| Q2 2023 | 45 | $3.10M |
| Q1 2023 | 12 | $1.15M |
| Q4 2022 | 16 | $1.70M |
| Q3 2022 | 11 | $1.00M |
| Q2 2022 | 13 | $504.0K |
| Q1 2022 | 25 | $1.76M |
| Q4 2021 | 21 | $5.96M |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q1 2022
Shares, value and share of portfolio for each institution holding MiNK Therapeutics, Inc.; share changes are against Q4 2021.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Morgan Stanley | 90 | $0 | 0.00% | −42,480−99.8% | Reduced |
| Citigroup Inc | 79 | $0 | 0.00% | −830−91.3% | Reduced |
| Royal Bank of Canada | 124 | $0 | 0.00% | −361−74.4% | Reduced |
| Ameritas Investment Partners, Inc. | 150 | $0 | 0.00% | 00.0% | Unchanged |
| FMR LLC | 157 | $0 | 0.00% | +157 | New |
| Deutsche Bank AG | 12 | $0 | 0.00% | +12 | New |
| Wells Fargo & Company | 445 | $1.00K | 0.00% | −762−63.1% | Reduced |
| Barclays PLC | 327 | $1.00K | 0.00% | +327 | New |
| Amalgamated Bank | 295 | $1.00K | 0.00% | +295 | New |
| Amalgamated Financial Corp. | 295 | $1.00K | 0.00% | +295 | New |
| American International Group, Inc. | 996 | $2.00K | 0.00% | −41−4.0% | Reduced |
| JPMorgan Chase & Co | 941 | $2.00K | 0.00% | +941 | New |
| California State Teachers Retirement System | 709 | $2.00K | 0.00% | +709 | New |
| Bank of America Corp | 1,995 | $5.00K | 0.00% | +148+8.0% | Added |
| Tower Research Capital LLC (TRC) | 2,269 | $5.00K | 0.00% | +443+24.3% | Added |
| UBS Group AG | 5,361 | $12.0K | 0.00% | +1,427+36.3% | Added |
| New York State Common Retirement Fund | 8,000 | $18.0K | 0.00% | 00.0% | Unchanged |
| Vanguard Group Inc | 10,348 | $23.0K | 0.00% | −423−3.9% | Reduced |
| State Street Corp | 16,776 | $38.0K | 0.00% | +4,847+40.6% | Added |
| BlackRock Inc. | 17,644 | $40.0K | 0.00% | +7,245+69.7% | Added |
| Renaissance Technologies LLC | 25,760 | $58.0K | 0.00% | −9,340−26.6% | Reduced |
| Geode Capital Management, LLC | 33,904 | $76.0K | 0.00% | +10,329+43.8% | Added |
| Bridgeway Capital Management, LLC | 35,500 | $80.0K | 0.00% | +35,500 | New |
| Artal Group S.A. | 289,588 | $652.0K | 0.03% | 00.0% | Unchanged |
| Sofinnova Investments, Inc. | 331,002 | $745.0K | 0.06% | −14,497−4.2% | Reduced |
| RTW Investments, LP | 0 | $0 | 0.00% | −416,666−100.0% | Sold out |
| Millennium Management LLC | 0 | $0 | 0.00% | −68,509−100.0% | Sold out |
| Gyon Technologies Capital Management, LP | 0 | $0 | 0.00% | −42,448−100.0% | Sold out |
| Invesco Ltd. | 0 | $0 | 0.00% | −21,066−100.0% | Sold out |